Presentation AHA 2022 Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial Presenter: Gregg W. Stone November 07, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Conference News AHA 2021 No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis Michael O'Riordan November 15, 2021
News Conference News AHA 2019 ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events Shelley Wood November 16, 2019
News Conference News AHA 2015 RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life L.A. McKeown November 09, 2015
News Conference News AHA 2015 Inappropriate PCIs Slashed by Half Since First AUC Released, But Key Questions Remain Shelley Wood November 08, 2015